inhibitor < inhibitors < inhibitory

Facettes :

List of bibliographic references indexed by inhibitors

Number of relevant bibliographic references: 13.

Ident.	Authors (with country if any)	Title
000545 (2010)	Stuart H. Isaacson [États-Unis]	Selective MAO‐B inhibitors have low potential for the tyramine effect
001015 (2007)	Stefano Zoccolella [Italie] ; Giovanni Iliceto [Italie] ; Michele Demari [Italie] ; Paolo Livrea [Italie] ; Paolo Lamberti [Italie]	Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
001178 (2006)	Moussa B. H. Youdim [Israël] ; Dale Edmondson [États-Unis] ; Keith F. Tipton [Irlande (pays)]	The therapeutic potential of monoamine oxidase inhibitors
001428 (2005)	Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis]	Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations
001571 (2004)	Kevin St. P. Mcnaught [États-Unis] ; Daniel P. Perl [États-Unis] ; Anna-Liisa Brownell [États-Unis] ; C. Warren Olanow [États-Unis]	Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
001600 (2004)	Rinat Tabakman [Israël] ; Shimon Lecht [Israël] ; Philip Lazarovici [Israël]	Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
001606 (2004)	Natalie J. Ives ; Rebecca L. Stowe ; Joanna Marro ; Carl Counsell ; Angus Macleod ; Carl E. Clarke ; Richard Gray ; Keith Wheatley	Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
001879 (2002)		MAO‐B inhibitors for the treatment of Parkinson's disease
001C57 (2000)	Cheryl Waters [États-Unis]	Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease
002278 (1995)	A. Fredriksson ; T. Archer [Suède]	Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice
002815 (1989)	F. Boomsma [Pays-Bas] ; D. Meerwaldt [Pays-Bas] ; J. Man In'T Veld [Pays-Bas] ; A. Hovestadt [Pays-Bas] ; H. Schalekamp [Pays-Bas]	Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa
002A84 (1983)	P. Riederer [Autriche] ; K. Jellinger [Autriche]	Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline)
002B41 (1981)	C. J. Fowler [Irlande (pays)] ; L. Oreland [Suède] ; B. A. Callingham [Royaume-Uni]	The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J‐508: their properties and applications

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "inhibitors" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "inhibitors" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    inhibitors
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024